Purpose: MLN8237, a selective small-molecule inhibitor of Aurora kinase A, has activity in a broad range of preclinical pediatric cancer models. We conducted a phase I trial in children with refractory/recurrent solid tumors to define the maximum-tolerated dose, toxicities, and pharmacokinetic properties of MLN8237.
Introduction
The Aurora family of serine/threonine protein kinases plays a critical role in the regulation of chromosomal segregation and cytokinesis during mitotic progression. Aurora A and B are expressed in all actively dividing cells, whereas Aurora C expression is largely restricted to dividing germ cells (1) . Aurora A is critical for mitotic spindle assembly and stability as well as regulation of centrosomal and kinetochore formation (2, 3) . The Aurora A kinase gene is amplified or overexpressed in many tumors, including colon, ovarian (4), pancreatic (5) , and bladder cancers (6, 7) . Aurora A overexpression is associated with aneuploidy and centrosome amplification, and overexpression of Aurora A kinase results in the transformation of normal cells (8) , supporting the hypothesis that Aurora A is an oncogene (9) . Reports have shown that in cultured cells, reduction of Aurora A using RNA interference (RNAi) reduces Aurora A protein content and results in mitotic spindle defects, mitotic delay, and apoptosis (10) .
MLN8237 is a selective small-molecule inhibitor of Aurora A kinase being developed for treatment of advanced malignancies. The safety experience in adults on a 7-day schedule in cycles repeated every 21 days supports a recommended phase II dose of 50 mg orally twice daily (11, 12) . The most commonly observed adverse events are generally reversible and include neutropenia, thrombocytopenia, mucositis, alopecia, and asthenia; other adverse events include transient schedule-dependent somnolence and confusion, consistent with the benzodiazepine-like effects of MLN8237 (11, 12) .
MLN8237 has shown activity against a broad range of both in vitro and in vivo preclinical models (13) . Because of promising results from the Pediatric Preclinical Testing Program (PPTP) showing substantial preclinical activity in neuroblastoma and leukemia (13) , MLN8237 was prioritized for rapid clinical development in pediatrics.
Patients and Methods
Institutional Review Boards at participating institutions approved the study. Informed consent was obtained from patients, ages 18 years or older, or from parents/legal guardians of children aged less than 18 years, with child assent when appropriate, according to individual institutional policies.
Patients and eligibility
Eligible patients were younger than 22 years with a recurrent or refractory solid tumor, excluding central nervous system (CNS) tumors or known CNS metastatic disease. Patients were required to have a Karnofsky or Lansky performance score of at least 50 for those older or younger than 16 years, respectively. Adequate bone marrow function (absolute neutrophil count !1,000/mL, platelet count !100,000/mL, and hemoglobin !8 gm/dL), renal (normal serum creatinine for age), and hepatic [total bilirubin 1.5Â normal and alanine aminotransferase (ALT) 5.0Â upper limit of normal, for this study, the upper limit of normal was 45 U/L] function was required. Patients were required to have recovered from the acute toxic effects of all prior treatment and should not have received myelosuppressive chemotherapy within 3 weeks of study entry; palliative radiation within 2 weeks or radiation to more than 50% of the pelvis or craniospinal axis within 6 months; or biologic therapy or growth factors within 7 days; or stem cell transplantation within 3 months. Patients were required to be able to swallow capsules. Exclusion criteria included uncontrolled infection, pregnancy or lactation, concurrent administration of certain P-glycoprotein substrates (digoxin, cyclosporine, tacrolimus, or sirolimus), and use of daily benzodiazepines because of the potential benzodiazepine-like effects of MLN8237.
Study design
This dose-escalation study used a rolling-six design (14) . Briefly, up to 6 patients were enrolled concurrently at the starting dose. Enrollment to subsequent dose levels was determined by the number of enrolled patients, the number with dose-limiting toxicity (DLT), and the number at risk for DLT. Toxicity was graded according to Common Terminology Criteria for Adverse Events v3.0. Hematologic DLT was defined as MLN8237-related grade 4 neutropenia for greater than 7 days, grade 4 thrombocytopenia on 2 separate days, or requiring platelet transfusion on 2 separate days, within a 7-day period, or myelosuppression that caused a delay of 14 days or more between treatment cycles. Nonhematologic DLT was defined as any grade 3 or 4 nonhematologic toxicity possibly, probably, or definitely attributable to MLN8237 with the exception of the following grade 3 toxicities: nausea or vomiting that resolved within 3 days, fever, infection, or serum mineral or electrolyte disturbances that resolved with oral supplementation. Any toxicity that resulted in a treatment delay of greater than 14 days was considered dose limiting. The maximum tolerated dose (MTD) was exceeded if 2 or more subjects in a cohort of 2 to 6 subjects experienced a DLT during cycle 1.
Dose escalation, drug formulation, and administration MLN8237 (Millennium Pharmaceuticals, Inc.) was administered orally once daily (part A1) or twice daily (part A2) for 7 days, every 21 days. The starting dose was 45 mg/m 2 per os once daily, with dose escalation to 60, 80, and 100 mg/m 2 . Following completion of enrollment to part A1 (once-daily dosing), patients enrolled on part A2 (twice-daily dosing) and received 40 mg/m 2 per os twice daily (80 mg/m 2 total daily dose) or 30 mg/m 2 per os twice daily (60 mg/m 2 total daily dose). A dosing nomogram based on body surface area was used to determine the daily dose in each patient using MNL8237 capsules (2.5, 5, and 25 mg). Capsules were swallowed intact by patients who had been fasting for 1-hour before and 1-hour after dose.
Response
Subjects were evaluable for response if they received 1 complete cycle of MLN8237. Disease evaluations were conducted at baseline and before cycle 2 and then every other treatment cycle. Response Evaluation Criteria in Solid Tumors (RECIST) criteria were used for response assessment (15) . The overall response rate was based on best response. Responses were required to be sustained
Translational Relevance
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for a minimum of 2 consecutive imaging evaluations at least 6 weeks apart. All institutional reports of response or prolonged stable disease (!6 cycles) were confirmed by central radiographic review.
Pharmacokinetic studies
Serial blood samples for pharmacokinetic studies of MLN8237 were obtained on day 1, cycle 1 in consenting patients. Whole blood (3 mL) was collected in K 2 EDTA before, and 0.5, 1, 2, 4, 6 to 8, and 24 hours after the first dose. For patients receiving twice-daily dosing (n ¼ 7), the second dose of MLN8237 on day 1 was not administered to permit sampling at 24 hours and estimation of the terminal half-life. Blood samples were stored refrigerated on wet ice for up to 48 hours and then centrifuged. Plasma was stored at À80
C. The MLN8237 concentration in plasma was quantified using a validated liquid chromatography/tandem mass spectrometry method with a lower limit of quantification of 10 nmol/L and interday reproducibility less than 5% (16) . The MLN8237 plasma concentration-time data were analyzed using noncompartmental methods. The peak concentration (C max ) and time to peak concentration (T max ) were determined from a concentration-time curve for each patient. Area under the concentration curve to the last measured time point (AUC 0-last ) was calculated using the linear trapezoidal method and extrapolated to infinity (AUC 0-¥ ) by adding the final measured plasma concentration divided by the terminal rate constant, which was derived from the slope of the natural log-transformed concentrations and times on the terminal elimination phase of the decay curve. The half-life was determined by dividing 0.693 by the terminal rate constant. Apparent clearance (CL/F) was calculated by dividing the actual dose administered to the patient by the AUC 0-¥ .
Results
Thirty-seven patients were enrolled onto the study from October 2008 to September 2009 (Table 1) . Five patients were not fully assessable for toxicity: 2 patients were deemed ineligible (1 patient each did not meet minimum recovery period after receiving radiotherapy or a biologic agent) and 3 were deemed inevaluable for toxicity assessment before completion of the first cycle. , with 3 of 4 subjects experiencing 5 total DLTs, including grade 4 neutropenia, grade 4 platelets, and a delay in platelet recovery to more than 100,000/mL resulting in a delay of 14 days or more between treatment cycles. Therefore, the MTD on part A1 was 80 mg/m 2 per os once daily for 7 days, every 21 days. Table 3 lists the nondose-limiting hematologic and nonhematologic toxicities observed in all patients during cycle 1. In patients treated at the MTD, nonDLTs during cycle 1 included hematologic toxicity and mood alteration.
The study was amended to allow for twice-daily dosing to evaluate whether this schedule could decrease neurotoxicity by lowering the maximum plasma drug concentration (C max ). In part A2, 11 patients were fully evaluable for toxicity. At the 80 mg/m 2 /dose twice daily), 1 of 5 patients developed transient grade 4 alkaline phosphatase elevation. In addition, 5 of 11 patients experienced nondose-limiting hand-footskin syndrome, manifested as erythema and peeling, on the twice-daily dosing regimen.
Thirteen of 21 patients on part A1 and 5 of 11 patients on part A2 experienced transient, fully reversible neurotoxicity (grade 1-4) during cycle 1 ( Table 4 ). All neurotoxicity was transient and reversible. In addition, a greater proportion of patients receiving twice-daily dosing experienced hematologic toxicity or hand-foot-skin syndrome. One patient on the once-daily dosing developed grade 2 hand-foot-skin syndrome. Because of DLT and nondose-limiting toxicity profile in patients receiving 30 mg/m 2 twice daily, enrollment to part A2 was discontinued. The toxicity profile did not change for patients receiving up to 13 cycles in part A1 and 5 cycles in part A2. Neurologic and hematologic toxicity did not seem to be cumulative.
The MTD and recommended dose of MLN8237 in children with refractory or relapse solid tumors is 80 mg/m 2 per os once daily for 7 days followed by 2 weeks rest (21-day treatment cycle).
Pharmacokinetic studies
The average plasma concentration-time profiles of MLN8237 at each dose level are presented in Fig. 1 . MLN8237 was rapidly absorbed after an oral dose, with a median (range) T max of 2.3 (1.1-3.1) hours. MLN8237 plasma pharmacokinetic parameters for the 13 subjects with complete serial pharmacokinetic sampling are summarized in Table 5 . The AUC 0-¥ increased in proportion to the dose over the dosage range from 30 to 100 mg/m 2 . Wide interpatient variability in drug disposition was observed with a median (range) apparent clearance (CL/F) of 34 (16-59) mL/min/m 2 .
Best response
In the 33 response-evaluable subjects, (23 measurable disease, 10 evaluable disease only) a median of 1 cycle (range 1-35) was administered. In those with measurable disease, 1 patient with hepatoblastoma had a partial response (PR) and 6 patients had stable disease (2 neuroblastoma and 4 sarcoma for 10, 35, 7, 13, 5, and 5 cycles, respectively). Two patients with evaluable disease, both with neuroblastoma, had stable disease for 6 and 9 cycles. There was not a significant difference in the number of prior therapies in the subjects with PR/SD compared with the subjects who had progressive disease. There was also no difference in response between subjects who received oncedaily dosing versus those who received twice-daily dosing.
Discussion
MLN8237 is a small-molecule reversible inhibitor of AURKA that acts via competition with ATP binding. A recent review on mitotic kinase inhibitors (17) focused on the relatively limited antitumor activity seen with these agents in adult trials, raising concern that the mitotic proteins (Aurora A, B, and C), may not be a productive drug development pathway to pursue. On the basis of preclinical data and the results of the current trial, these concerns may not necessarily translate over into the pediatric realm.
The MTD of MLN8237 in children with solid tumors, 80 mg/m 2 /d administered orally once daily for 7 days, is approximately 1.5-fold greater than the adult MTD of 50 mg twice daily for 7 days. Overall, toxicities were similar to those observed in adults, with hematologic toxicities being the most common DLT observed in children. Although the twice-daily dosing regimen seemed to be well tolerated in adult studies, the schedule did not prove to be better tolerated in children who developed more frequent myelosuppression causing delays and hand-foot-skin syndrome.
This is the first phase I trial in children to use the rollingsix design, which allows enrollment of up to 6 patients at a dose level versus the standard 3, in an attempt to shorten overall study duration by eliminating the observation period when a cohort is expanded from 3 to 6. Although the overall performance of this design cannot be assessed from a single trial, we note that it did not result in an apparent increased risk in toxicity. A comprehensive analysis of this trial design will be possible after the completion of more trials that use the design. Despite the wide interpatient variability in drug disposition, the systemic MLN8237 exposure (AUC) seemed to increase in proportion to dose. Correlation of plasma pharmacokinetic parameters to toxicity may have been limited by the small sample size on this study, although we did observe that patients with any grade of neurotoxicity during cycle 1 had a higher median C max (5.7 vs. 3.6 mmol/L, P < 0.05) and AUC (69.7 vs. 47.8 mmol/L * h, P < 0.05) compared with those without neurotoxicity.
MLN8237 showed broad and potent activity against both acute lymphoblastic leukemia (ALL) and neuroblastoma panels in preclinical models. The dose and schedule used in PPTP experiments (20 mg/kg twice daily for 5 days for 6 weeks consecutively in solid tumor xenografts and for 3 weeks consecutively for ALL xenografts) was predicted to prove tolerable in humans. However, the adult phase I experience proved these to be overestimates. Despite limited clinical activity observed on the current trial, the number of patients studied at the MTD is too small to provide for a good assessment for efficacy. The preclinical data, coupled with the observations that children tolerate 1.5-fold greater doses than adult patients do, support moving forward with the ongoing phase II program in pediatrics. Important considerations for future development of this agent will include the availability of a liquid formulation for younger children and definition of the mechanism by which Aurora kinase A provides a potential oncogenic vulnerability to a subset of pediatric cancer cells, as genomic amplification does not seem to be a driving event but stabilization of myelocytomatosis viral related oncogene, neuroblastomaderived may be important (18) .
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